Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trial
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae135 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Ying Xiong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Linyi People's Hospital, Linyi, China. Hauptthemen laut MEDLINE: Niacinamide, Salicylic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Shanghai RuiZhi Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Background
Chloasma is a common skin hyperpigmentation condition, with treatment options ranging from topical agents to advanced interventions such as chemical peels and laser therapy. Salicylic acid, including its supramolecular form (SSA), has shown promise in managing chloasma. However, to date, no multicentre randomized controlled trial of SSA for chloasma is available.
Objectives
The purpose of this study was to assess the efficacy and safety of 30% SSA combined with 10% niacinamide in treating chloasma.
Methods
This multicentre (n = 15), randomized, double-blind, parallel placebo-controlled trial (Clinical trial registration number: ChiCTR2200065346) enrolled and randomized 300 participants (1 : 1) to either 30% SSA treatment or placebo, with 150 allocated to treatment and 150 to placebo in the full analysis set, and 144 to treatment and 147 to placebo in the per-protocol set. A Visia® Skin Analysis System was used at each visit to assess the degree of improvement in chloasma lesions. The primary endpoint was the effective rate after 16 weeks, assessed using the modified Melasma Area and Severity Index (mMASI) score [(pretreatment score − post-treatment score)/pretreatment score × 100%].
Results
The total mMASI score, overall score on the Griffiths 10-point scale, and Griffiths 10 score for the left and the right sides of the face were significantly lower in the 30% SSA group than in the placebo group (all P < 0.001). One study of drug-related adverse events (AEs) and one study of drug-unrelated AEs were reported in the 30% SSA group. No AE was reported in the placebo group.
Conclusions
Among our patients, 30% SSA combined with 10% niacinamide was shown to be effective and safe for treating chloasma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Linyi People's Hospital, Linyi, China.
- Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Dermatology, The First Affiliated Hospital of China Medical University, Shenyang, China.
- Department of Dermatology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Dermatology, Xining First People's Hospital, Xining, China.
Förderung
- Shanghai RuiZhi Pharmaceutical Co., Ltd
Zitieren
APA
Xiong, Y., Jiang, X., Lai, W., Gao, X., You, Y., Huang, Y., Li, X., Zhang, J., Tao, S., Chen, J., Zhang, W., Yu, N., Xu, N., Liu, C., Zeng, W., Lv, S., & Wang, G. (2024). Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trial. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae135
Vancouver
Xiong Y, Jiang X, Lai W, Gao X, You Y, Huang Y, et al. Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trial. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae135
BibTeX
@article{Xiong2024,
author = {Xiong, Ying and Jiang, Xian and Lai, Wei and Gao, Xinghua and You, Yan and Huang, Yongmei and Li, Xueli and Zhang, Junling and Tao, Shiqin and Chen, Jin and Zhang, Wei and Yu, Nan and Xu, Nan and Liu, Chunling and Zeng, Weihui and Lv, Shichao and Wang, Gang},
title = {Supramolecular salicylic acid combined with niacinamide in chloasma: a randomized controlled trial},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae135}
}
EUVIMED